• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Daily 12 mg dexamethasone not superior to 6 mg for severe COVID-19 infection

byJake EngelandMichael Pratte
October 26, 2021
in Emergency, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This multi-centered, randomized controlled trial demonstrated that 12 mg and 6 mg dexamethasone daily had similar efficacy for days alive without life support and safety at 28 days for patients hospitalized with severe COVID-19.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recent clinical trials have demonstrated that systemic glucocorticoids reduce short-term mortality in patients with a severe COVID-19 infection. Some of these trials showed that higher doses of dexamethasone are effective in patients with acute respiratory distress syndrome outside of a COVID-19 infection. Currently, 6 mg of dexamethasone daily is recommended to treat severe and critical COVID-19. This multi-centred, randomized controlled trial (COVID STEROID 2) investigated whether a higher dose of dexamethasone (12 mg) improves clinical outcomes compared to 6 mg in critical COVID-19 patients with hypoxemia. Patients were included if they were hospitalized with COVID-19 and required: supplemental oxygen at a rate of a minimum of 10L/min, non-invasive ventilation with continuous positive airway pressure for hypoxemia, or invasive mechanical ventilation. Patients were randomly assigned 12 mg (461/497 included in the analysis) or 6 mg (446/485 included in the analysis) of dexamethasone daily. The primary outcome was the number of days living without life support (invasive mechanical ventilation, circulatory support, kidney replacement therapy) at 28 days post-randomization. The duration of treatment was similar between both groups (median: 7 days [IQR: 5.0-9.0] vs. median 7 days [IQR: 6.0-9.0] in the 12-mg and 6-mg cohorts, respectively). The median number of days alive without life support at 28 days was similar between groups (22.0 days [IQR:6.0-28.0] vs. 20.5 days [IQR: 4.0-28.0] in the 12-mg and 6-mg cohorts, respectively; adjusted mean difference: 1.3 days [95% CI: 0-2.6 days]; p= 0.07). Additionally, serious adverse events (septic shock, invasive fungal infection, significant gastrointestinal bleeding) were similar between cohorts (11.3% in the 12-mg group vs. 13.4% in the 6-mg group; adjusted relative risk: 0.83 [99% CI: 0.54-1.29]). Overall, 12 mg of dexamethasone daily demonstrated no significantly short-term clinical improvement compared to 6 mg. Notably, treatment for COVID-19 changed in the middle of this trial (use of IL-6 receptor antagonists) which could have interfered with the outcomes of this study.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Dexamethasone in hospitalized patients with Covid-19

Image: PD

RELATED REPORTS

Methylprednisolone after hip replacement surgery improves pain and sleep quality

Evolving standard of care guidelines have improved outcomes in hospitalized COVID-19 patients

Long COVID syndrome may be associated with insomnia and excessive sleepiness

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: corticosteroidcovidcovid-19 infectiondexamethasoneglucocorticoid
Previous Post

BNT162b2 COVID-19 vaccine may reduce hospitalizations from SARS-CoV-2 delta variant for up to six months

Next Post

Association of cardiac and non-cardiac comorbidities with adverse outcomes of atrial fibrillation

RelatedReports

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Surgery

Methylprednisolone after hip replacement surgery improves pain and sleep quality

January 24, 2023
Palliative chemotherapy associated with more ICU treatment at end-of-life
Infectious Disease

Evolving standard of care guidelines have improved outcomes in hospitalized COVID-19 patients

December 23, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Long COVID syndrome may be associated with insomnia and excessive sleepiness

November 21, 2022
Plagiocephaly/brachycephaly associated with lower cognitive and academic achievement scores
Wellness

Wellness Check: Sleep

November 17, 2022
Next Post
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Association of cardiac and non-cardiac comorbidities with adverse outcomes of atrial fibrillation

#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

#VisualAbstract: Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer

#VisualAbstract: Implant-based breast reconstruction with acellular dermal matrix does not reduce reoperation rates

#VisualAbstract: Gemcitabine plus cisplatin improves overall survival compared to fluorouracil plus cisplatin in metastatic or recurrent nasopharyngeal carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options